Clinical biopharmaceutical company, Liquidia dedicated to accelerate the performance of precision medicine by accurately engineering drug particles announces to commence the evolution of a Phase 3 Clinical trial LIQ861 ensuring mitigation of pulmonary arterial hypertension in order to impede disease progression and enhance quality of life by alleviating symptoms and surging functional class. LIQ861 is initiated using Liquidia’s proprietary Print technology designed to penetrate deep down into lungs using a disposable, dry- powder inhaler. PAH Is a patent disease occurs owing to hardening and narrowing of the pulmonary arteries leading to heart- failure at times. Trepostinil, formerly sanctioned by U.S Food and Drug Administration in oral, nebulized and parenteral formulations, is an analog of prostacyclin, a vasoactive mediator deficient patients with PAH yet vital to efficient functioning of lungs to control vessel tone.
Neal Fowler, CEO at Liquidia Technologies mentions “LIQ861 shows the potential of our PRINT technology to optimize safety, efficacy and convenience of therapeutics. The initiation of our trial marks an important milestone for Liquidia, for those living with PAH and for the PAH community at large. We believe that we are well positioned to advance LIQ861 through Phase 3 clinical development.”.
Liquidia desires to roll out atleast 100 patients with PAH across varied U.S sites in the open – label phase 3 Clinical Trial. Liquidia expects to admit the first patient within the next few weeks. The objectives of the trial are long- term safety and tolerability of LIQ861. March, 2017, marked the completion of Liquidia phase 1 clinical trial on healthy volunteers who showed high levels of tolerance at all doses. Predicting an additional collation of data from this Phase 1 trial at scientific conferences in 2018, Final conclusive data is set to be collated and declared in 2019. Liquidia to initiate Phase 3 clinical trials solely on the response elicited from the FDA thus promulgating U.S regulatory approval of LIQ861.
Image Source: Liquidia Technologies